Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The functional antagonism between SIRT2 and MOF regulates cell cycle progression and genome stability [ChIP-seq]

ABSTRACT: The control of G2/M transition is a key event for genome stability as it ensures proper completion of DNA replication and repair before progressing into mitosis. One of the key regulators of G2/M checkpoint is the H4K16Ac-acetyltransferase MOF, which plays a major role in chromatin structure, gene expression, DNA damage and genome stability. Here we show that SIRT2, a member of the sirtuin family of NAD+-dependent deacetylases, antagonizes the role of MOF in G2/M. SIRT2 promotes specific inactivation of MOF through deacetylation and degradation of MOF, which results in re-expression of G2/M cell-cycle genes regulated by MOF. Underscoring the functional relevance of this antagonism, both factors play opposed roles in the deposition of the key mark H4K20me1 during G2/M. Consistently, loss of MOF in wt but not in SIRT2-/- cells induces a genome-wide deregulation of H4K20me1 distribution, which results in a premature loading of condensins. Our studies suggest that the G2/M checkpoint is shaped by the balance between both factors and involves condensing regulation and underscores the role of sirtuins in cell cycle control and genome stability under stress.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE277367 | GEO | 2026/05/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The functional antagonism between SIRT2 and MOF regulates cell cycle progression and genome stability [RNA-seq]

Project description:The control of G2/M transition is a key event for genome stability as it ensures proper completion of DNA replication and repair before progressing into mitosis. One of the key regulators of G2/M checkpoint is the H4K16Ac-acetyltransferase MOF, which plays a major role in chromatin structure, gene expression, DNA damage and genome stability. Here we show that SIRT2, a member of the sirtuin family of NAD+-dependent deacetylases, antagonizes the role of MOF in G2/M. SIRT2 promotes specific inactivation of MOF through deacetylation and degradation of MOF, which results in re-expression of G2/M cell-cycle genes regulated by MOF. Underscoring the functional relevance of this antagonism, both factors play opposed roles in the deposition of the key mark H4K20me1 during G2/M. Consistently, loss of MOF in wt but not in SIRT2-/- cells induces a genome-wide deregulation of H4K20me1 distribution, which results in a premature loading of condensins. Our studies suggest that the G2/M checkpoint is shaped by the balance between both factors and involves condensing regulation and underscores the role of sirtuins in cell cycle control and genome stability under stress.

2026-05-06 | GSE277368 | GEO

The functional antagonism between SIRT2 and MOF regulates mitotic entry - MOF interactors

Project description:Mitosis entry is tightly regulated by a complex network of interconnected mechanisms involving epigenetic modifications, signaling pathways, transcriptional control, and structural changes. While significant progress has been made in understanding these processes individually, the mechanisms integrating chromatin dynamics with key mitotic regulators are still not fully understood. Here, we identify a functional antagonism between the deacetylase SIRT2 and the acetyltransferase MOF in the G2/M transition and mitotic progression. This interplay, which involves MOF deacetylation by SIRT2, regulates key histone marks, including H4K16ac deacetylation and H4K20me1 deposition, condensin II loading, the stability of the key mitotic regulator PLK1 and has a major impact on the transcription control of mitosis regulated by the FOXM1. Our findings reveal a previously unrecognized layer of regulation in G2/M progression, shedding light on the intricate crosstalk between chromatin dynamics and mitotic control, with potential implications for understanding chromosomal stability and cancer.

2026-04-29 | PXD065214 | Pride

The functional antagonism between SIRT2 and MOF regulates mitotic entry - PLK1 methylation

2026-04-29 | PXD065218 | Pride

Sirt2 inhibition reprograms T cell metabolism for optimal anti-tumor immunity: Sirt2 Interacting Proteins

Project description:Growing evidence indicates that metabolism is a key driver of T cell functions. A switch from oxidative phosphorylation to aerobic glycolysis is a hallmark of T cell activation and is required to meet metabolic demands of proliferation and effector functions. However, the mechanisms underlying the metabolic switch in T cells remain unclear. Here, we identify Sirt2 as a crucial immune checkpoint coordinating metabolic and functional fitness of T cells. Sirt2 is induced upon T cell activation and increases in late maturation stages. Sirt2 negatively regulates glycolysis by targeting key glycolytic enzymes. Remarkably, Sirt2 knockout T cells exhibit profound upregulation of aerobic glycolysis with enhanced proliferation and effector function and thus effectively reject tumor challenge in vivo. Furthermore, pharmacologic inhibition of Sirt2 in human tumor infiltrating lymphocytes demonstrated a similar phenotype. Taken together, our results demonstrate Sirt2 as an actionable target to reprogram T cell metabolism to augment immunotherapy.

2020-06-15 | PXD012811 | Pride

Sirt2 inhibition reprograms T cell metabolism for optimal anti-tumor immunity: Sirt2 Interacting Proteins 2

2020-07-03 | PXD020150 | Pride

Sirt2 Inhibition Reprograms T Cell Metabolism to Confer Superior Anti-Tumor Immunity

Project description:Metabolism is a key driver of T cell functions, and the switch from oxidative-phosphorylation to aerobic glycolysis is a hallmark of T cell activation. However, the mechanisms underlying the metabolic switch remain unclear. Here, we report that the Sirtuin-2 (Sirt2) deacetylase protein functions as a metabolic checkpoint that harnesses T cell effector functions and impairs anti-tumor immunity. Specifically, upregulation of Sirt2 expression in human tumor-infiltrating T lymphocytes (TILs) negatively correlates with response to Nivolumab and TIL therapy in non-small cell lung cancer. Mechanistically, Sirt2 suppresses aerobic glycolysis by deacetylating key glycolytic enzymes. Accordingly, Sirt2-deficient T cells manifest increased glycolysis, display enhanced proliferation and effector functions, and have superior anti-tumor activity. Importantly, pharmacologic inhibition of Sirt2 endows human TILs with these superior metabolic fitness and enhanced effector functions. These findings indicate Sirt2 as an actionable target for reprogramming T cell metabolism to augment a broad spectrum of cancer immunotherapies.

2020-09-16 | GSE151421 | GEO

Sirt2 inhibition reprograms T cell metabolism for optimal anti-tumor immunity: Lysine Acetylation

2020-06-15 | PXD012796 | Pride

Essential Role of Sirt2 in Type I Interferon Signaling

Project description:We provide evidence for the essential role of Sirt2 in IFN mediated signaling. Our studies demonstrate that SIRT2 controls expression of key interferon stimulated genes (ISGs) that mediate important biological functions, including anti-viral and antineoplastic responses.

2015-12-31 | GSE66033 | GEO

Sirt2 Inhibition Reprograms T Cell Metabolism to Confer Superior Anti-Tumor Immunity

Project description:Dysregulated metabolism is a key driver of maladaptive tumor-reactive T lymphocytes within the tumor microenvironment (TME). Actionable mechanisms that rescue the effector activity of anti-tumor T cells in a metabolically restricted TME remain elusive. Here, we report that the Sirtuin-2 (Sirt2) protein deacetylase functions as a master metabolic checkpoint that inhibits T cell metabolic fitness and impairs T cell effector functions and anti-tumor immunity. Mechanistically, Sirt2 suppresses glycolysis and oxidative-phosphorylation (OxPhos) by deacetylating key enzymes involved in glycolysis, tricarboxylic acid (TCA)-cycle, fatty acid oxidation (FAO) and glutaminolysis. Accordingly, Sirt2-deficient T cells exhibit a hyper-metabolic activity with increased glycolysis and OxPhos, resulting in enhanced proliferation and effector functions at tumor beds and subsequently exhibiting superior anti-tumor activity. Importantly, pharmacologic inhibition of Sirt2 endows human lung tumor-infiltrating lymphocytes (TILs) with these superior metabolic fitness and enhanced effector functions. Furthermore, upregulation of Sirt2 expression in human TILs negatively correlates with response to Nivolumab and TIL therapy in non-small cell lung cancer (NSCLC). Our findings unveil Sirt2 as an unexpected actionable target for reprogramming T cell metabolism to augment a broad spectrum of cancer immunotherapies.

2020-06-16 | PXD019763 | Pride

Hypoxia-induced alterations of G2 checkpoint regulators

Project description:Hypoxia promotes an aggressive tumor phenotype with increased genomic instability, partially due to downregulation of DNA repair pathways. However, in addition to DNA repair, genome stability is also controlled by cell cycle checkpoints. An important issue is therefore whether hypoxia also can alter the DNA damage cell cycle checkpoints. Here, we show that hypoxia (24h 0.2% O2) alters the expression of several G2 checkpoint regulators, as examined by microarray gene expression analysis and immunoblotting of U2OS cells. While some of the changes reflected hypoxia-induced inhibition of cell cycle progression, flow cytometric bar-coding analysis of individual cells showed that the levels of several G2 checkpoint regulators were reduced in G2 phase cells after hypoxic exposure, in particular cyclin B1. These effects were accompanied by decreased Cyclin dependent kinase (CDK) activity in G2 phase cells after hypoxia. Furthermore, cells pre-exposed to hypoxia showed a longer G2 checkpoint arrest upon treatment with ionizing radiation. Similar results were found following other hypoxic conditions (~0.03 % O2 20h and 0.2% O2 72h). These results demonstrate that the DNA damage G2 checkpoint can be altered as a consequence of hypoxia, and we propose that such alterations may influence the genome stability of hypoxic tumors. We measured gene expression changes in U2OS cells after treatment with 0.2% hypoxia for 24 hours. The data were used in the exploration of hyopxia induced alterations in the G2 checkpoint.

2016-01-04 | E-GEOD-70530 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data